Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
JCO Clinical Cancer Informatics · 2024
DOI: 10.1200/cci.24.00132 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Gurjyot K Doshi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Texas Oncology, Houston, TX. Hauptthemen laut MEDLINE: Ipilimumab, Carcinoma, Renal Cell, Nivolumab, Kidney Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Nivolumab plus ipilimumab (NIVO + IPI) is a first-in-class combination immunotherapy for the treatment of intermediate- or poor (I/P)-risk advanced or metastatic renal cell carcinoma (mRCC). Currently, there are limited real-world data regarding clinical effectiveness beyond 12-24 months from treatment initiation. In this real-world study, treatment patterns and clinical outcomes were evaluated for NIVO + IPI in a community oncology setting. METHODS A retrospective analysis using electronic medical record data from The US Oncology Network examined patients with I/P-risk clear cell mRCC who initiated first-line (1L) NIVO + IPI between January 4, 2018, and December 31, 2019, with follow-up until June 30, 2022. Baseline demographics, clinical characteristics, treatment patterns, clinical effectiveness, and safety outcomes were assessed descriptively. Overall survival (OS) and real-world progression-free survival (rwPFS) were analyzed using Kaplan-Meier methods. RESULTS Among 187 patients identified (median follow-up, 22.4 months), with median age 63 (range, 30-89) years, 74 (39.6%) patients had poor risk and 37 (19.8%) patients had Eastern Cooperative Oncology Group performance status score ≥2. Of 86 patients who received second-line therapy, 54.7% received cabozantinib and 10.5% received pazopanib. The median (95% CI) OS and rwPFS were 38.4 (24.7-46.1) months and 11.1 (7.5-15.0) months, respectively. Treatment-related adverse events (TRAEs) were reported in 89 (47.6%) patients, including fatigue (n = 25, 13.4%) and rash (n = 19, 10.2%). CONCLUSION This study provides data to support the understanding of the real-world utilization and long-term effectiveness of 1L NIVO + IPI in patients with I/P-risk mRCC. TRAE rates were low relative to clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Texas Oncology, Houston, TX.
- Ontada, Boston, MA.
- Bristol Myers Squibb, Princeton, NJ.
ORCID-Profile: Andrew J Osterland, Samantha Eiffert
Zitieren
APA
Doshi, G. K., Osterland, A. J., Shi, P., Yim, A., Del Tejo, V., Guttenplan, S. B., Eiffert, S., Yin, X., Rosenblatt, L., & Conkling, P. R. (2024). Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00132
Vancouver
Doshi GK, Osterland AJ, Shi P, Yim A, Del Tejo V, Guttenplan SB, et al. Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.24.00132
BibTeX
@article{Doshi2024,
author = {Doshi, Gurjyot K and Osterland, Andrew J and Shi, Ping and Yim, Annette and Del Tejo, Viviana and Guttenplan, Sarah B and Eiffert, Samantha and Yin, Xin and Rosenblatt, Lisa and Conkling, Paul R},
title = {Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States},
journal = {JCO Clinical Cancer Informatics},
year = {2024},
doi = {10.1200/cci.24.00132}
}
EUVIMED